Life Science Today

Unique therapies including anti-opioid overdose, ocular implants, fish skin, UV light, digital therapeutics, and the impact of approvals

Originally Published as The Niche Podcast.

Find out more at
https://LifeScienceTodayPodcast.com

Story References
https://tinyurl.com/Niche-074-1
https://tinyurl.com/Niche-074-2
https://tinyurl.com/Niche-074-3
https://tinyurl.com/Niche-074-4
https://tinyurl.com/Niche-074-5
https://tinyurl.com/Niche-074-6
https://tinyurl.com/Niche-074-7
https://tinyurl.com/Niche-074-8

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

The 26-year pipeline, CMDO divestment, oncology, and movement among COVID19 Therapies
 

Originally Published as The Niche Podcast.

Find out more at
https://LifeScienceTodayPodcast.com


Story References
https://tinyurl.com/Niche-073-1
https://tinyurl.com/Niche-073-2
https://tinyurl.com/Niche-073-3
https://tinyurl.com/Niche-073-4
https://tinyurl.com/Niche-073-5
https://tinyurl.com/Niche-073-6

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Less than spiffy SPACs, big brains big money, Malaria buzz, vaccines, tests, series A, and Voyager gets a renewed lease on life

Originally Published as The Niche Podcast.

Find out more at
https://LifeScienceTodayPodcast.com

Story References
https://tinyurl.com/Niche-072-1
https://tinyurl.com/Niche-072-2
https://tinyurl.com/Niche-072-3
https://tinyurl.com/Niche-072-4
https://tinyurl.com/Niche-072-5
https://tinyurl.com/Niche-072-6
https://tinyurl.com/Niche-072-7
https://tinyurl.com/Niche-072-8

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

$11.5B acquisitions, we play “Who’s on First”, COVID19 therapy news, cancer Vaccines may be on the way, and CAR T for cancer is here to stay

Originally Published as The Niche Podcast.

Find out more at
https://LifeScienceTodayPodcast.com


Story References
https://tinyurl.com/Niche-071-1
https://tinyurl.com/Niche-071-2
https://tinyurl.com/Niche-071-3
https://tinyurl.com/Niche-071-4
https://tinyurl.com/Niche-071-5
https://tinyurl.com/Niche-071-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Double approval, double acquisition, $200M for tests, $200M for prostate robots, $450M for $1B worth of gummies

Originally Published as The Niche Podcast.

Find out more at
https://LifeScienceTodayPodcast.com

Story References
https://tinyurl.com/Niche-070-1
https://tinyurl.com/Niche-070-2
https://tinyurl.com/Niche-070-3
https://tinyurl.com/Niche-070-4
https://tinyurl.com/Niche-070-5
https://tinyurl.com/Niche-070-6
https://tinyurl.com/Niche-070-7

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

BeiGene’s oncology machine, China oncology pipelines, COVID costs, two new FDA approvals, $5B life science merger, and Hong Kong joins US SPAC party

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-069-1
https://tinyurl.com/Niche-069-2
https://tinyurl.com/Niche-069-3
https://tinyurl.com/Niche-069-4
https://tinyurl.com/Niche-069-5
https://tinyurl.com/Niche-069-6
https://tinyurl.com/Niche-069-7
https://tinyurl.com/Niche-069-8

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

$1.5B deal, $1.9B merger, protein degraders get backing, an old bird has new tricks, and another billion-dollar valuation for CRISPR

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-068-1
https://tinyurl.com/Niche-068-2
https://tinyurl.com/Niche-068-3
https://tinyurl.com/Niche-068-4
https://tinyurl.com/Niche-068-5
https://tinyurl.com/Niche-068-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

This week, I go on vacation and give you a special bonus interview with Sam Searcy, founder and CEO of CliniStart and former NC State Senator

Find out more at
https://thenichepod.com

Story References
https://clinistart.com/
https://www.samsearcy.com/
https://www.linkedin.com/in/samuel-searcy-3462891a4/

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast
The Cassava saga, Reify goes big… too big? Humacyte SPAC, vax news you already know, and a new growth hormone therapy – approved!

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-066-1
https://tinyurl.com/Niche-066-2
https://tinyurl.com/Niche-066-3
https://tinyurl.com/Niche-066-4
https://tinyurl.com/Niche-066-5
https://tinyurl.com/Niche-066-6
https://tinyurl.com/Niche-066-7

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast
Alphabet buys, uncertain futures, new biotech funds, HIF-2a, PD-1, and a China Biotech emerges.

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-065-1
https://tinyurl.com/Niche-065-2
https://tinyurl.com/Niche-065-3
https://tinyurl.com/Niche-065-4
https://tinyurl.com/Niche-065-5
https://tinyurl.com/Niche-065-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.